Literature DB >> 14592898

Susceptibility of ocular tissues to autoimmune diseases.

Henry J Kaminski1, Zhuyi Li, Chelliah Richmonds, Robert L Ruff, Linda Kusner.   

Abstract

The orbital tissues may form a unique immunological environment, as evidenced by autoimmune disorders that specifically target orbital tissues, particularly myasthenia gravis (MG) and Graves' ophthalmopathy (GO). The reasons for the preferential susceptibility are likely to be multiple, based on the interplay of molecular and physiological properties of extraocular muscles (EOM), the unique requirements of the ocular motor system, and the specific autoimmune pathology. Of general importance, even a minor loss of EOM force generation will sufficiently misalign the visual axes to produce dramatic symptoms, and proprioceptive feedback is limited to overcome such a deficit. Particular to MG, EOM synapses appear susceptible to neuromuscular blockade, the autoimmune pathology differs between ocular and generalized MG patients, and the influence of complement regulatory factors may be less prominent in preventing damage at EOM neuromuscular junctions. GO pathogenesis is poorly understood, but shared epitopes of orbital fibroblasts, EOM, and thyroid could lead to specific autoimmune targeting of these tissues. The differential response of orbital fibroblasts to cytokines may be a key factor in disease development. Greater appreciation of the immunologic environment of orbital tissues may lead to therapies specifically designed for orbital autoimmune diseases.

Entities:  

Mesh:

Year:  2003        PMID: 14592898     DOI: 10.1196/annals.1254.043

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN: 0077-8923            Impact factor:   5.691


  8 in total

1.  Perimysial fibroblasts of extraocular muscle, as unique as the muscle fibers.

Authors:  Linda L Kusner; Andrew Young; Steven Tjoe; Patrick Leahy; Henry J Kaminski
Journal:  Invest Ophthalmol Vis Sci       Date:  2009-08-06       Impact factor: 4.799

2.  Immunohistochemical studies using immunized Guinea pig sera with features of anti-human thyroid, eye and skeletal antibody and Graves' sera.

Authors:  Ildikó Molnár; Zita Szombathy; Ilona Kovács; A József Szentmiklósi
Journal:  J Clin Immunol       Date:  2007-01-23       Impact factor: 8.317

3.  Identification of the neuromuscular junction transcriptome of extraocular muscle by laser capture microdissection.

Authors:  Caroline Ketterer; Ulrike Zeiger; Murat T Budak; Neal A Rubinstein; Tejvir S Khurana
Journal:  Invest Ophthalmol Vis Sci       Date:  2010-04-14       Impact factor: 4.799

4.  Extraocular muscle susceptibility to myasthenia gravis: unique immunological environment?

Authors:  Jindrich Soltys; Bendi Gong; Henry J Kaminski; Yuefang Zhou; Linda L Kusner
Journal:  Ann N Y Acad Sci       Date:  2008       Impact factor: 5.691

5.  RNA expression analysis of passive transfer myasthenia supports extraocular muscle as a unique immunological environment.

Authors:  Yuefang Zhou; Henry J Kaminski; Bendi Gong; Georgiana Cheng; Jason M Feuerman; Linda Kusner
Journal:  Invest Ophthalmol Vis Sci       Date:  2014-06-10       Impact factor: 4.799

6.  Extraocular muscle characteristics related to myasthenia gravis susceptibility.

Authors:  Rui Liu; Hanpeng Xu; Guiping Wang; Jie Li; Lin Gou; Lihua Zhang; Jianting Miao; Zhuyi Li
Journal:  PLoS One       Date:  2013-02-08       Impact factor: 3.240

7.  Characterisation of 11beta-hydroxysteroid dehydrogenase 1 in human orbital adipose tissue: a comparison with subcutaneous and omental fat.

Authors:  Iwona J Bujalska; Omar M Durrani; Joseph Abbott; Claire U Onyimba; Pamela Khosla; Areeb H Moosavi; Tristan T Q Reuser; Paul M Stewart; Jeremy W Tomlinson; Elizabeth A Walker; Saaeha Rauz
Journal:  J Endocrinol       Date:  2007-02       Impact factor: 4.286

Review 8.  Complicating autoimmune diseases in myasthenia gravis: a review.

Authors:  Aliona Nacu; Jintana Bunpan Andersen; Vitalie Lisnic; Jone Furlund Owe; Nils Erik Gilhus
Journal:  Autoimmunity       Date:  2015-04-27       Impact factor: 2.815

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.